Department of Systems Medicine, University of Roma "Tor Vergata", Via Montpellier 1, 00135, Rome, Italy.
Department of Experimental Medicine and Surgery, University of Roma "Tor Vergata", Via Montpellier 1, Rome, 00135, Italy.
J Neural Transm (Vienna). 2019 Mar;126(3):319-325. doi: 10.1007/s00702-019-01979-0. Epub 2019 Feb 12.
Evidence suggests that physical activity (PA) exerts beneficial effects on neurodegenerative processes, either as symptomatic relief or disease-modifying strategy. Actually, it may represent a viable neuroprotective intervention in Parkinson's disease dementia (PDD), a severe, frequent, and untreatable complication of Parkinson's disease (PD). According to such hypothesis, this cross-sectional study tested, in PD patients, the association between levels of PA and well-known risk factors for PDD, such as mood disorders and amyloid-β42 CSF content. Amount of PA was measured by the International Physical Activity Questionnaires-Short Form (IPAQ-SF) in 128 cognitively intact PD patients and correlated with the Hamilton-Depression (HAM-D) and the Hamilton-Anxiety (HAM-A) scores; in a homogenous subgroup of 40 patients, it was further correlated with a panel of CSF biomarkers, including amyloid-β42, total α-synuclein, total, and phosphorylated tau. The statistical model was corrected for the main potential confounding factors (motor impairment, dopaminergic treatment, disease duration, age, and sex). Both the HAM-A and HAM-D scores, as well as the Aβ42 CSF content, improved in parallel with the increase of the total week amount of PA. Although with several limitations, we preliminarily demonstrated that a high level of PA is associated with a more favourable profile of PDD risk factors, in terms of both mood disturbances and CSF markers of neurodegeneration. However, confirmative studies are necessary to validate the efficacy of PA as protective intervention for PDD.
有证据表明,体力活动(PA)对神经退行性过程有有益的影响,无论是作为症状缓解还是疾病修饰策略。实际上,它可能代表了一种可行的神经保护干预措施,可以用于治疗帕金森病痴呆症(PDD),这是一种严重、频繁且无法治愈的帕金森病(PD)并发症。基于这一假说,本横断面研究在 PD 患者中测试了 PA 水平与 PDD 的已知风险因素(如情绪障碍和 Aβ42 CSF 含量)之间的相关性。PA 量通过国际体力活动问卷-短表(IPAQ-SF)进行测量,共纳入 128 名认知功能完整的 PD 患者,并与汉密尔顿抑郁量表(HAM-D)和汉密尔顿焦虑量表(HAM-A)评分相关;在 40 名同质亚组患者中,进一步与包括 Aβ42、总α-突触核蛋白、总tau 和磷酸化 tau 在内的一组 CSF 生物标志物相关联。统计模型校正了主要潜在混杂因素(运动障碍、多巴胺治疗、疾病持续时间、年龄和性别)。HAM-A 和 HAM-D 评分以及 Aβ42 CSF 含量均随 PA 总周量的增加而平行改善。尽管存在一些局限性,我们初步证明高水平的 PA 与 PDD 风险因素的更有利的特征相关,无论是在情绪障碍还是神经退行性 CSF 标志物方面。然而,需要进一步的研究来验证 PA 作为 PDD 保护干预的疗效。
J Neural Transm (Vienna). 2019-2-12
Dement Geriatr Cogn Disord. 2006
Front Aging Neurosci. 2025-5-14
Front Aging Neurosci. 2024-1-16
J Neural Transm (Vienna). 2024-2
Sensors (Basel). 2023-2-12
Int J Environ Res Public Health. 2022-11-12
J Neural Transm (Vienna). 2021-8
Parkinsonism Relat Disord. 2018-10-15
J Neural Transm (Vienna). 2018-6-14
Neurobiol Learn Mem. 2018-5-23
Brain Plast. 2015-10-9
Lancet Neurol. 2018-4-23
Ann Neurol. 2018-5-11
Alzheimers Dement (Amst). 2018-2-6
Front Neurosci. 2018-2-7